GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...

UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced data from the Phase IIIb VOLITION study.

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...